eculizumab

[키워드] Activation Acute kidney injury acute respiratory distress acute respiratory distress syndrome AMY-101 Angiogenesis apoptotic cells ARDS Biomarker bradykinin candidate drug candidate drugs cascade cascade system characterized chemokines Coagulation Coagulation system complement Complement inhibitor complement inhibitors Compound COVID-19 Crosstalk cytokine Cytokines damaged demonstrated dysregulation ecallantide eculizumab Evidence favor ground glass opacities heparin High dose high risk Icatibant IL-6 IL-6 levels in some incidence include Influenza influenza-like symptom Influenza-like symptoms inhibitor initiated Innate innate immune system intensive care treatment Kallikrein lanadelumab lead leukocytes life-threatening LMWH Lung injury mechanical ventilation mechanism moderate MOST oxygen oxygen saturation pandemic pathophysiology Patient patients Phase I plasma plasma proteins Platelets Potential predict Prevent Prognostic value pulmonary damage pulmonary inflammation receptor reduced Regulation respiratory distress Respiratory distress syndrome SARS-CoV-2 SARS-CoV-2 infected patient severity Support survival syndrome System systemic target the disease therapeutic option therapeutic options Thromboembolism thrombosis thrombotic Thrombotic complications translated Treatment treatment of COVID-19 Trial Usage Vascular ventilator virus
[DOI] 10.3389/fimmu.2022.840137 PMC 바로가기 [Article Type] Review